507231-28-9Relevant academic research and scientific papers
Method for preparing isothiocyanate from ethyl chloroformate
-
Paragraph 0050; 0052, (2018/05/16)
The invention relates to a method for preparing isothiocyanate from ethyl chloroformate. The method comprises the following steps: taking a compound as shown in specification as a starting material, reacting with carbon disulfide to prepare inner salt, and then reacting the inner salt with ethyl chloroformate in an organic solvent at the temperature of 0-40 DEG C to prepare thio-mixed anhydride, wherein in the compound as shown in specification, n is 1, 2, 3, 4 or 5; and adding the mixed anhydride in an inorganic aqueous alkali, and hydrolyzing at the temperature of minus 5-30 DEG C to preparethe corresponding isothiocyanate. According to the preparation method, the mixed anhydride is synthesized at first, and then is hydrolyzed with inorganic alkali, application of organic alkali is avoided effectively, side reaction of the isothiocyanate and alcohol is relieved, and the reaction yield of the isothiocyanate and the purity of the product are improved.
5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
-
Page/Page column 10, (2008/06/13)
The invention concerns novel 5-sulphanyl-4H-1,2,4-triazole derivatives of formula (1), wherein: R1, R2 and R3 represent variable groups and the methods for preparing them by liquid-phase parallel synthesis processes. Said product exhibit good affinity for certain sub-types of somatostatin receptors; they are particularly useful for treating pathological conditions or diseases wherein one (or more) somatostatin receptors is (are) involved. The invention also concerns pharmaceutical compositions containing said products and their use for preparing a medicine.
Regioselective covalent modification of hemoglobin in search of antisickling agents
Park, Soobong,Hayes, Brittany L.,Marankan, Fatima,Mulhearn, Debbie C.,Wanna, Linda,Mesecar, Andrew D.,Santarsiero, Bernard D.,Johnson, Michael E.,Venton, Duane L.
, p. 936 - 953 (2007/10/03)
Although the molecular defect in sickle hemoglobin that produces sickle cell disease has been known for decades, there is still no effective drug treatment that acts on hemoglobin itself. In this work, a series of diversely substituted isothiocyanates (R-NCS) were examined for their regioselective reaction with hemoglobin in an attempt to alter the solubility properties of sickle hemoglobin. Electrospray mass spectrometry, molecular modeling, X-ray crystallography, and conventional protein chemistry were used to study this regioselectivity and the resulting increase in solubility of the modified hemoglobin. Depending on the attached R-group, the isothiocyanates were found to react either with the Cysβ93 or the N-terminal amine of the α-chain. One of the most effective compounds in the series, 2-(N,N-dimethylamino)ethyl isothiocyanate, selectively reacts with the thiol of Cysβ93 which, in conjunction with the cationic group, was seen to perturb the local hemoglobin structure. This modified HbS shows an approximately 30% increase in solubility for the fully deoxygenated state, along with a significant increase in oxygen affinity. This compound and a related analogue appear to readily traverse the erythrocyte membrane. A discussion of the relation of these structural changes to inhibition of gelation is presented. The dual activities of increasing HbS oxygen affinity and directly inhibiting deoxy HbS polymerization, in conjunction with facile membrane traversal, suggest that these cationic isothiocyanates show substantial promise as lead compounds for development of therapeutic agents for sickle cell disease.
